Covid-19: Covaxin effective against Delta plus variant, says ICMR study

"We have evaluated the IgG antibody titer and neutralizing potential of sera of COVID naive individuals full doses of BBV152 vaccine, COVID recovered cases with full dose vaccines and breakthrough cases post immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the ICMR study said;

Published On 2021-08-03 04:00 GMT | Update On 2024-02-14 09:08 GMT

New Delhi: Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in biorxivby the Indian Council of Medical and Research (ICMR).

"Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19 naive individuals full doses of BBV152 vaccine, Covid-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the study said.

Also Read: Brazil shelves import authorisation of Bharat Biotech Covaxin

The recent emergence of the SARS-CoV-2 Variant B.1.617.2 (Delta) variant with its high transmissibility has led to the second wave in India.

Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial.

Subsequently, Delta has further mutated to Delta AY.1, AY.2, and AY.3.

Of these, AY.1 variant was first detected in India in April 2021 and subsequently from 20 other countries as well, the study said.

The study is a pre-print and has not been peer reviewed.

Covaxin demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2per centprotection against the B.1.617.2 Delta variant, Bharat Biotech had said while concluding the final analysis of Covaxin efficacyfrom Phase3 trials on July 3.

Also Read: Covid-19: CDSCO panel nod to trial of mixing Covaxin, Covishield doses

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Covid-19: Covaxin effective against Delta plus variant, says ICMR study

"We have evaluated the IgG antibody titer and neutralizing potential of sera of COVID naive individuals full doses of BBV152 vaccine, COVID recovered cases with full dose vaccines and breakthrough cases post immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the ICMR study said;

Similar News

NTRUHS invites applications for BAMS, BHMS, BUMS admissions 2025, check details

Gujarat BAMS, BHMS Round 1 admissions choice filling open till September 8, check seat matrix

Govt committed to State-Specific SOPs to boost Ayush Integration: Shri Prataprao Jadhav

AYUSH Ministry to host 2-day National Summit to boost capacity building

Ayurveda Day to be celebrated annually on September 23

Ayush industry moving towards USD 200 billion target, says Union Minister Prataprao Jadhav

30th National Ayurveda Seminar to Focus on Paediatric Health and Wellness

Ayush Ministry's Consultative Committee to convene first meeting on August 19